Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Summary

The goal of this clinical research study is to learn if cilengitide given in combination with bevacizumab can help to control glioblastoma. The safety of this drug combination will also be studied. Cilengitide is designed to block the flow of blood to cancer cells, which may help to slow or block the growth of cancer. Bevacizumab is designed to block the growth of new blood vessels, which may help to slow or block the growth of cancer.

Timeline

Start

2013-06

Primary completion

2017-06

Completion

—

Drugs

Indications